- Home
- HMST vs AVIR Comparison
HMST vs AVIR Comparison
Compare HMST & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- AVIR
- Stock Information
- Founded
- HMST 1921
- AVIR 2012
- Country
- HMST United States
- AVIR United States
- Employees
- HMST N/A
- AVIR N/A
- Industry
- HMST Major Banks
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- HMST Finance
- AVIR Health Care
- Exchange
- HMST Nasdaq
- AVIR Nasdaq
- Market Cap
- HMST 287.6M
- AVIR 247.5M
- IPO Year
- HMST 2012
- AVIR 2020
- Fundamental
- Price
- HMST $10.78
- AVIR $3.26
- Analyst Decision
- HMST Buy
- AVIR Hold
- Analyst Count
- HMST 2
- AVIR 1
- Target Price
- HMST $14.75
- AVIR $6.88
- AVG Volume (30 Days)
- HMST 153.6K
- AVIR 503.8K
- Earning Date
- HMST 01-27-2025
- AVIR 11-07-2024
- Dividend Yield
- HMST N/A
- AVIR N/A
- EPS Growth
- HMST N/A
- AVIR N/A
- EPS
- HMST N/A
- AVIR N/A
- Revenue
- HMST $169,710,000.00
- AVIR N/A
- Revenue This Year
- HMST N/A
- AVIR N/A
- Revenue Next Year
- HMST $12.08
- AVIR N/A
- P/E Ratio
- HMST N/A
- AVIR N/A
- Revenue Growth
- HMST N/A
- AVIR N/A
- 52 Week Low
- HMST $8.09
- AVIR $2.75
- 52 Week High
- HMST $16.10
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- HMST 37.17
- AVIR 53.11
- Support Level
- HMST $10.60
- AVIR $3.10
- Resistance Level
- HMST $11.95
- AVIR $3.32
- Average True Range (ATR)
- HMST 0.46
- AVIR 0.14
- MACD
- HMST -0.05
- AVIR 0.03
- Stochastic Oscillator
- HMST 10.81
- AVIR 87.61
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).